Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05MBJ
|
||||
| Former ID |
DNC014023
|
||||
| Drug Name |
1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529603] | ||
| Formula |
C18H21NO3
|
||||
| Canonical SMILES |
CC(=O)C1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
|
||||
| InChI |
1S/C18H21NO3/c1-14(20)16-13-22-18(19-16)17(21)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
|
||||
| InChIKey |
YLVGVXYZOJMUNJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [529603] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.